Combination of circulating miR-145-5p/miR-191-5p as biomarker for breast cancer detection.
Biomarker
Breast cancer
Circulating miRNA
Diagnosis
Kazakh population
Plasma
miR-145
miR-191
miR-21
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
06
2020
accepted:
13
11
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
Breast cancer (BC) is the most common cancer among women worldwide. At present, there is a need to search for new, accurate, reliable, minimally invasive and cheap biomarkers in addition to existing methods for the diagnosis and prognosis of BC. The main goal of this study was to test the diagnostic value of six circulating miRNAs in Kazakh women. TaqMan-based miRNA profiling was conducted using plasma specimens from 35 BC women patients and 33 healthy women samples (control group). The level of all seven miRNAs (including endogenous control) normalized by synthetic cel-miR-39 were significantly elevated in the group of BC patients. Normalization using miR-222-3p as endogenous control reduced differences in level of miRNAs between groups; as a result, only three miRNAs were significantly upregulated in the group of BC patients-miR-145-5p ( Two plasma miRNAs-miR-145-5p and miR-191-5p-are potential biomarkers for diagnosis of BC in the Kazakh population. The findings need to be further substantiated using a more representative sample.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer (BC) is the most common cancer among women worldwide. At present, there is a need to search for new, accurate, reliable, minimally invasive and cheap biomarkers in addition to existing methods for the diagnosis and prognosis of BC. The main goal of this study was to test the diagnostic value of six circulating miRNAs in Kazakh women.
MATERIALS AND METHODS
METHODS
TaqMan-based miRNA profiling was conducted using plasma specimens from 35 BC women patients and 33 healthy women samples (control group).
RESULTS
RESULTS
The level of all seven miRNAs (including endogenous control) normalized by synthetic cel-miR-39 were significantly elevated in the group of BC patients. Normalization using miR-222-3p as endogenous control reduced differences in level of miRNAs between groups; as a result, only three miRNAs were significantly upregulated in the group of BC patients-miR-145-5p (
CONCLUSIONS
CONCLUSIONS
Two plasma miRNAs-miR-145-5p and miR-191-5p-are potential biomarkers for diagnosis of BC in the Kazakh population. The findings need to be further substantiated using a more representative sample.
Identifiants
pubmed: 33362968
doi: 10.7717/peerj.10494
pii: 10494
pmc: PMC7749656
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10494Informations de copyright
©2020 Ashirbekov et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
Ann Intern Med. 2016 Feb 16;164(4):244-55
pubmed: 26756588
Iran J Public Health. 2020 Jan;49(1):21-29
pubmed: 32309220
BMC Res Notes. 2017 Jul 25;10(1):312
pubmed: 28743297
Mol Cancer. 2018 Oct 11;17(1):147
pubmed: 30309355
Carcinogenesis. 2012 Apr;33(4):828-34
pubmed: 22298638
Sensors (Basel). 2017 Jul 05;17(7):
pubmed: 28678153
Oncol Res Treat. 2017;40(7-8):423-429
pubmed: 28683441
Sci Rep. 2020 Mar 11;10(1):4526
pubmed: 32161294
Mol Oncol. 2012 Dec;6(6):590-610
pubmed: 23102669
Clin Cancer Res. 2008 Mar 1;14(5):1340-8
pubmed: 18316553
Cell Death Dis. 2017 Sep 7;8(9):e3045
pubmed: 28880270
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
PLoS One. 2018 Jan 16;13(1):e0191333
pubmed: 29338058
Sci Rep. 2015 Aug 27;5:13526
pubmed: 26311223
Clin Chem. 2015 Nov;61(11):1333-42
pubmed: 26408530
Drug Dev Res. 2015 Nov;76(7):343-53
pubmed: 26303294
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7735-7741
pubmed: 30536317
Tumour Biol. 2015 Jan;36(1):251-8
pubmed: 25238878
Nat Commun. 2020 Mar 19;11(1):1456
pubmed: 32193458
J Mol Diagn. 2013 Nov;15(6):827-34
pubmed: 23988620
Leukemia. 2012 Nov;26(11):2414-6
pubmed: 22504138
Sci Rep. 2019 Oct 17;9(1):14913
pubmed: 31624308
Cancer. 2012 May 15;118(10):2603-14
pubmed: 22370716
Sci Rep. 2017 Dec 4;7(1):16829
pubmed: 29203780
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3207-12
pubmed: 19202062
Breast Cancer. 2018 Mar;25(2):198-205
pubmed: 29101635
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
Trends Cancer. 2017 Mar;3(3):181-197
pubmed: 28718431
Mol Diagn Ther. 2020 Apr;24(2):153-173
pubmed: 32067191
PET Clin. 2018 Jul;13(3):339-354
pubmed: 30100074
Biomed Res Int. 2018 Jan 17;2018:6074808
pubmed: 29581979
Int J Clin Exp Med. 2015 Feb 15;8(2):1703-14
pubmed: 25932099
PLoS One. 2010 Oct 29;5(10):e13735
pubmed: 21060830
Front Immunol. 2017 Feb 16;8:56
pubmed: 28261196
Bioanalysis. 2014 May;6(9):1215-26
pubmed: 24946922
Dis Markers. 2013;34(3):163-9
pubmed: 23334650
PLoS One. 2017 Feb 2;12(2):e0167969
pubmed: 28151938
Clin Chim Acta. 2012 Jul 11;413(13-14):1058-65
pubmed: 22387599
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819828709
pubmed: 30786836
Oncol Lett. 2017 Jan;13(1):315-320
pubmed: 28123561
Mol Oncol. 2014 Jul;8(5):874-83
pubmed: 24694649
J Prev Med Public Health. 2017 Nov;50(6):401-410
pubmed: 29207445
Int J Mol Sci. 2019 Sep 05;20(18):
pubmed: 31491899
Pharmacol Ther. 2017 Apr;172:34-49
pubmed: 27916656
BMC Cancer. 2018 Apr 3;18(1):380
pubmed: 29615072
PLoS One. 2013 Dec 31;8(12):e83718
pubmed: 24391813
J Pak Med Assoc. 2017 Mar;67(3):446-450
pubmed: 28303998
Methods. 2010 Apr;50(4):298-301
pubmed: 20146939
Clin Chem. 2016 Jul;62(7):1002-11
pubmed: 27197674
Oncotarget. 2015 May 30;6(15):13387-401
pubmed: 26033453
Breast Cancer Res Treat. 2015 Nov;154(2):423-34
pubmed: 26476723
Mol Ther Oncolytics. 2018 Dec 31;12:173-194
pubmed: 30788428
J Nucl Med. 2016 Feb;57 Suppl 1:9S-16S
pubmed: 26834110
Cien Saude Colet. 2014 Jun;19(6):1813-24
pubmed: 24897481
Cancer. 2015 Nov 15;121(22):4062-70
pubmed: 26291519
Adv Biol Regul. 2015 Jan;57:1-9
pubmed: 25294678
CA Cancer J Clin. 2017 May 6;67(3):194-232
pubmed: 28436999
Clin Chim Acta. 2010 Dec 14;411(23-24):1869-74
pubmed: 20816948
BMC Cancer. 2019 Jul 27;19(1):738
pubmed: 31351450
Oncol Rep. 2014 Apr;31(4):1509-16
pubmed: 24573597
Cancer Discov. 2017 Jun;7(6):561-574
pubmed: 28495849
J Clin Invest. 2009 Apr;119(4):772-87
pubmed: 19287097
Cancer Metastasis Rev. 2015 Mar;34(1):145-55
pubmed: 25721950
Carcinogenesis. 2016 May;37(5):461-70
pubmed: 26785733
J Med Screen. 2016 Mar;23(1):31-7
pubmed: 26265482
Mol Pharm. 2020 Apr 6;17(4):1114-1126
pubmed: 32176509
PLoS One. 2013;8(1):e53141
pubmed: 23301032
Carcinogenesis. 2018 Dec 31;39(12):1506-1516
pubmed: 30084985
Oncotarget. 2017 Oct 31;8(60):102119-102133
pubmed: 29254230
Bioimpacts. 2016;6(1):25-31
pubmed: 27340621
Yonsei Med J. 2017 Nov;58(6):1101-1110
pubmed: 29047233